AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma

Br J Cancer. 2001 Nov 2;85(9):1396-9. doi: 10.1054/bjoc.2001.2102.


Malignancy of neoplasms is partly dependent on angiogenesis. Angiotensin II mediates angiogenesis and transcription of growth-related factors through stimulation of the AT1 receptor (AT1R). Losartan, a drug used mostly for treatment of hypertension, binds strongly to this receptor. We found the presence of AT1 receptor on C6 glioma cells and studied the effect of Losartan on the growth and angiogenesis of C6 rat glioma; Losartan in dose of 80 mg/kg induced 79% reduction of tumoural volume with a significant decrease of vascular density, mitotic index and cell proliferation. Our results demonstrate the conspicuous presence of AT1R in malignant glial cells and a favourable therapeutic response in experimental glioma by selective blockage of the AT1 receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology*
  • Brain Neoplasms / pathology*
  • Cell Division
  • Glioma / pathology*
  • Losartan / pharmacology*
  • Neovascularization, Pathologic / physiopathology*
  • Rats
  • Receptor, Angiotensin, Type 1
  • Receptors, Angiotensin / genetics*
  • Tumor Cells, Cultured


  • Antihypertensive Agents
  • Receptor, Angiotensin, Type 1
  • Receptors, Angiotensin
  • Angiotensin II
  • Losartan